Florastor (Saccharomyces boulardii) is NOT recommended as primary treatment for C. difficile infection
Florastor should not be used as monotherapy for C. difficile infection (CDI). The most recent IDSA/SHEA 2021 guidelines make no mention of probiotics, including Saccharomyces boulardii, in the treatment algorithm for CDI 1. The standard treatment remains vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg twice daily for 10 days for initial episodes 1.
When Florastor May Be Considered (Adjunctive Use Only)
For recurrent CDI only, Saccharomyces boulardii may be added to standard antibiotic therapy, though this is not included in current IDSA/SHEA guidelines:
Dosing Regimen for Adjunctive Use:
- Dose: 1 gram (approximately 10 billion CFU) orally twice daily
- Duration: Start with antibiotic therapy and continue for 4 weeks total
- Timing: Must be given concurrently with vancomycin or fidaxomicin, not as monotherapy
Evidence Supporting Adjunctive Use:
The most recent high-quality study 2 from 2025 showed that adding S. boulardii to vancomycin:
- Reduced recurrence rate from 13.1% to 1.7% (p=0.032)
- Increased global cure rate from 85.3% to 96.6% (p=0.044)
- Did not affect initial clinical cure rates (both ~98%)
Historical data 3 demonstrated efficacy specifically in recurrent CDI (recurrence rate 34.6% with S. boulardii vs 64.7% with placebo, p=0.04), but showed no benefit for initial CDI episodes (19.3% vs 24.2%, p=0.86).
Critical Caveats and Contraindications:
Do NOT use Florastor in:
- Immunocompromised patients (AIDS, active chemotherapy)
- Central venous catheter recipients - risk of fungemia is 0.26 cases per 1,000 central-line days 4
- ICU patients - 6.55-fold increased risk of S. cerevisiae bloodstream infection 4
- Patients with severe/fulminant CDI - requires immediate aggressive antibiotic therapy
Important Limitations:
The AGA 2020 guidelines 5 explicitly state: "The AGA makes no recommendations for the use of probiotics in the treatment of C. difficile infection" due to heterogeneous data, high risk of bias in studies, and concerns about publication bias.
The evidence quality is low to very low for treatment of active CDI 6. Most benefit is seen when combined with high-dose vancomycin (2g/day) rather than standard doses 7.
Practical Algorithm:
Initial CDI episode:
- Use vancomycin or fidaxomicin alone
- Do NOT add S. boulardii (no proven benefit) 3
First recurrence:
- Preferred: Fidaxomicin or tapered/pulsed vancomycin 1
- Consider adding S. boulardii 1g twice daily for 4 weeks if using vancomycin
Second or subsequent recurrence:
- Standard antibiotic therapy per guidelines 1
- May add S. boulardii 1g twice daily for 4 weeks
- Screen for contraindications (immunosuppression, central lines)
Prevention context only:
- S. boulardii may reduce risk of developing CDI when given with high-risk antibiotics (ceftriaxone, fluoroquinolones) 8, 9
- This is prevention, not treatment
The FDA labeling 10 lists only vague digestive complaints and does not specifically mention CDI treatment, reflecting the lack of regulatory approval for this indication.